|Venture Round, 1/12 |
Avila Therapeutics is a clinical-stage biotechnology company focused on the design and development of targeted covalent drugs to achieve best-in class outcomes. This approach, called â€œprotein silencingâ€, cannot be achieved through traditional chemistry techniques. The companyâ€™s product pipeline has been built using its proprietary Avilomicsâ„¢ platform and is currently focused on cancer, viral infection and autoimmune disease. Avilaâ€™s most advanced product candidate, AVL-292, a potential treatment for cancer and autoimmune diseases, is currently in Phase 1 clinical testing. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners.